Demographic, clinical, and biological data on 14 patients treated with rituximab for rheumatoid arthritis
| Case | Sex/age/duration of disease (y) | No of prior DMARD/prior anti-TNF (Y/N) | Non-articular involvement (Y/N) | No of infusions × dose (mg)/No of MP pulses/concomitant IS | Adverse event (Y/N) | Efficacy RA/non-articular involvement (Y/N) | Time to response (w)/follow up (m) | DAS28 initial/last† | Prednisone initial/last‡ (mg/d) | RF initial/last (IU/ml) (n <20) | Relapse (Y/N)/time to relapse (m) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| *Evolution of neutropenia in patients 13 and 14 was described in a submitted case report. | |||||||||||
| †p<0.0002 between DAS28 value pre- and post-treatment using paired t test. | |||||||||||
| ‡p<0.01 between prednisone dose pre- and post-treatment. | |||||||||||
| CPH, cyclophosphamide; DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; F, female; HQ, hydroxychloroquine; IS, immunosuppressants; lymph, lymphoma; m, months; M, male; MP, methylprednisolone; MTX, methotrexate; N, no; NA, not available; neg, negative; pos, positive; RA, rheumatoid arthritis; RF, rheumatoid factor (determined by nephelometry, except where stated “pos/neg”, when determined by latex); TNF, tumour necrosis factor; w, weeks; y, years; Y, yes; –, not relevant. | |||||||||||
| 1 | F/48/4 | 8/Y | N | 4×375.m−2/HQ | N | Y | 4/6 | 5.9/2.9 | 15/10 | Pos/NA | N |
| 2 | M/83/3 | 3/Y | Y/lymph | 4×375.m−2/4/MP (100) | N | Y/Y | 6/5.5 | 7.6/2.4 | 12/9 | NA | Y/5.5 |
| 3 | F/42/15 | 11/Y | N | 27×375.m−2/MTX,CPH | N | Y | 16/15 | 8.3/3.6 | 10/10 | 270/150 | Y/5 |
| 4 | F/47/2 | 4/Y | N | 2×1000/2/MP (100)/MTX+HQ | N | Y | 4/3 | 8.7/4.7 | 0/0 | 240/122 | N |
| 5 | F/68/18 | 3/N | Y/lymph | 8×1000/8/CHOP | N | Y/Y | 4/24 | 5.3/2.7 | 3/0 | 266/20 | N |
| 6 | M/57/7 | 3/Y | N | 2×1000/CPH | N | Y | 4/5 | 6/3.2 | 20/10 | 938/441 | N |
| 7 | F/41/8 | 5/Y | N | 2×1000/MTX | N | N | –/4 | 6/5.2 | 10/10 | 95/NA | – |
| 8 | M/55/12 | 6/Y | N | 2×1000 | N | Y | 4/8 | 7.9/3.6 | 17.5/10 | Pos/neg | N |
| 9 | F/48/7 | 5/N | N | 2×1000/MTX | N | Y | 8/12 | 4/1.8 | 10/2.5 | Neg/neg | |
| 10 | M/49/3 | 7/Y | N | 1×375.m−2/1/MP (100) | Infusion related | N | –/3 | NA | 10/10 | Pos/pos | – |
| 11 | F/68/34 | 5/Y | N | 4×375.m−2/4/MP (40) | N | Y | 4/3 | 6.6/3.8 | 4/4 | NA | N |
| 12 | F/53/3 | 2/N | N | 4×375.m−2/4/MP (40) | N | Y | 6/6 | 6.5/2.2 | 4/0 | 20/20 | N |
| 13* | M/67/2 | 1/N | Y/Felty | 4×375.m−2 | N | N/N | –/6 | 6.6/6.7 | 15/15 | Neg/neg | – |
| 14* | M/53/4 | 2/N | Y/Felty | 4×375.m−2/MTX | N | Y/N | 4/12 | 7.5/2.1 | 15/10 | 60/14 | N |